Aurinia Pharmaceuticals Inc.
AUPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600620
In the last 90 days, Aurinia Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 282 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Aurinia Pharmaceuticals Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 186
- −3 vs. Q4 2022
- Shares held
- 50.5M
- −857.7K (−1.7%) vs. Q4 2022
- Total value
- $553.5M
- +$331.4M (+149.2%) vs. Q4 2022
- New holders
- 27
- 69 more added
- Sold out
- 30
- 46 more reduced
3 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 282 | $1.34B |
| Q1 2026 | 260 | $1.10B |
| Q4 2025 | 256 | $1.15B |
| Q3 2025 | 242 | $729.8M |
| Q2 2025 | 219 | $497.1M |
| Q1 2025 | 214 | $504.1M |
| Q4 2024 | 200 | $525.4M |
| Q3 2024 | 183 | $428.9M |
| Q2 2024 | 171 | $319.9M |
| Q1 2024 | 178 | $280.8M |
| Q4 2023 | 191 | $485.4M |
| Q3 2023 | 198 | $395.2M |
| Q2 2023 | 200 | $487.5M |
| Q1 2023 | 186 | $553.5M |
| Q4 2022 | 192 | $223.1M |
| Q3 2022 | 189 | $420.5M |
| Q2 2022 | 199 | $509.9M |
| Q1 2022 | 184 | $532.9M |
| Q4 2021 | 191 | $895.1M |
| Q3 2021 | 167 | $966.8M |
| Q2 2021 | 167 | $640.9M |
| Q1 2021 | 170 | $682.5M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Aurinia Pharmaceuticals Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −19,363−100.0% | Sold out |
| NinePointTwo Capital | 0 | $0 | 0.00% | −18,940−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −17,545−100.0% | Sold out |
| Douglas Lane & Associates, LLC | 0 | $0 | 0.00% | −12,200−100.0% | Sold out |
| BCS Wealth Management | 0 | $0 | 0.00% | −11,170−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −10,636−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −8,865−100.0% | Sold out |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −5,730−100.0% | Sold out |
| Money Concepts Capital Corp | 0 | $0 | 0.00% | −1,725−100.0% | Sold out |
| Fiduciary Alliance LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| RFP Financial Group LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −265−100.0% | Sold out |
| Castleview Partners, LLC | 0 | $0 | 0.00% | −70−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| HealthInvest Partners AB | – | – | – | – | Not filed |
| CoreCap Advisors, LLC | – | – | – | – | Not filed |
| Moser Wealth Advisors, LLC | – | – | – | – | Not filed |